STAT3 silencing in dendritic cells by siRNA polyplexes encapsulated in PLGA nanoparticles for the modulation of anticancer immune response

Molecular Pharmaceutics

Volumn 7, Issue 5, 2010, Pages 1643-1654

  Alshamsan, Aws ^a,b   Haddadi, Azita ^a,c   Hamdy, Samar ^a   Samuel, John ^a   El Kadi, Ayman O S ^a   Uludaǧ, Hasan ^a   Lavasanifar, Afsaneh ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

^b KING SAUD UNIVERSITY   (Saudi Arabia)

^c UNIVERSITY OF SASKATCHEWAN   (Canada)

Author keywords

Dendritic cells; PLGA, cancer immunotherapy; polyethylenimine; STAT3, siRNA

Indexed keywords

CD86 ANTIGEN; NANOPARTICLE; POLYETHYLENEIMINE; POLYGLACTIN; POLYGLACTIN POLYETHYLENEIMINE CONJUGATE; POLYGLACTIN STEARIC ACID CONJUGATE; SMALL INTERFERING RNA; STAT3 PROTEIN; STEARIC ACID DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL TISSUE; ANTIGEN EXPRESSION; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CANCER IMMUNOTHERAPY; CELL MATURATION; COMPLEX FORMATION; CONTROLLED STUDY; CYTOTOXICITY; DENDRITIC CELL; ENCAPSULATION; ENDOSOME; FLUORESCENCE MICROSCOPY; GENE SILENCING; IMMUNE RESPONSE; IMMUNOMODULATION; NONHUMAN; PRIORITY JOURNAL; TUMOR VOLUME; UPREGULATION; ZETA POTENTIAL;

ANIMALS; BASE SEQUENCE; BIOLOGICAL TRANSPORT, ACTIVE; CELL LINE, TUMOR; CELLS, CULTURED; DENDRITIC CELLS; GENE KNOCKDOWN TECHNIQUES; LACTIC ACID; MELANOMA, EXPERIMENTAL; MICE; MICROSCOPY, ELECTRON, SCANNING; NANOCAPSULES; NANOTECHNOLOGY; POLYETHYLENEIMINE; POLYGLYCOLIC ACID; RNA, SMALL INTERFERING; STAT3 TRANSCRIPTION FACTOR;

EID: 77957744000     PISSN: 15438384     EISSN: 15438392     Source Type: Journal    
DOI: 10.1021/mp100067u     Document Type: Article

References (57)

1. Banchereau, J.; Steinman, R. M. Dendritic cells and the control of immunity Nature 1998, 392 (6673) 245-52
2. Stockwin, L. H.; McGonagle, D.; Martin, I. G.; Blair, G. E. Dendritic cells: immunological sentinels with a central role in health and disease Immunol. Cell Biol. 2000, 78 (2) 91-102
3. Shortman, K.; Liu, Y. J. Mouse and human dendritic cell subtypes Nat. Rev. Immunol. 2002, 2 (3) 151-61
4. Steinman, R. M.; Banchereau, J. Taking dendritic cells into medicine Nature 2007, 449 (7161) 419-26
5. Steinman, R. M. Lasker Basic Medical Research Award. Dendritic cells: versatile controllers of the immune system Nat. Med. 2007, 13 (10) 1155-9
6. Kalinski, P.; Hilkens, C. M.; Wierenga, E. A.; Kapsenberg, M. L. T-cell priming by type-1 and type-2 polarized dendritic cells: the concept of a third signal Immunol. Today 1999, 20 (12) 561-7
7. Trombetta, E. S.; Mellman, I. Cell biology of antigen processing in vitro and in vivo Annu. Rev. Immunol. 2005, 23, 975-1028
8. Yang, L.; Carbone, D. P. Tumor-host immune interactions and dendritic cell dysfunction Adv. Cancer Res. 2004, 92, 13-27
9. Gabrilovich, D. Mechanisms and functional significance of tumour-induced dendritic-cell defects Nat. Rev. Immunol. 2004, 4 (12) 941-52
10. Turkson, J.; Jove, R. STAT proteins: novel molecular targets for cancer drug discovery Oncogene 2000, 19 (56) 6613-26
11. Yu, H.; Kortylewski, M.; Pardoll, D. Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment Nat. Rev. Immunol. 2007, 7 (1) 41-51
12. Gabrilovich, D. I.; Chen, H. L.; Girgis, K. R.; Cunningham, H. T.; Meny, G. M.; Nadaf, S.; Kavanaugh, D.; Carbone, D. P. Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells Nat. Med. 1996, 2 (10) 1096-103
13. Sumimoto, H.; Imabayashi, F.; Iwata, T.; Kawakami, Y. The BRAF-MAPK signaling pathway is essential for cancer-immune evasion in human melanoma cells J. Exp. Med. 2006, 203 (7) 1651-6
14. Kennedy, R.; Celis, E. Multiple roles for CD4+ T cells in anti-tumor immune responses Immunol. Rev. 2008, 222, 129-44
15. Park, S. J.; Nakagawa, T.; Kitamura, H.; Atsumi, T.; Kamon, H.; Sawa, S.; Kamimura, D.; Ueda, N.; Iwakura, Y.; Ishihara, K.; Murakami, M.; Hirano, T. IL-6 regulates in vivo dendritic cell differentiation through STAT3 activation J. Immunol. 2004, 173 (6) 3844-54
16. Cheng, F.; Wang, H. W.; Cuenca, A.; Huang, M.; Ghansah, T.; Brayer, J.; Kerr, W. G.; Takeda, K.; Akira, S.; Schoenberger, S. P.; Yu, H.; Jove, R.; Sotomayor, E. M. A critical role for Stat3 signaling in immune tolerance Immunity 2003, 19 (3) 425-36
17. Nefedova, Y.; Cheng, P.; Gilkes, D.; Blaskovich, M.; Beg, A. A.; Sebti, S. M.; Gabrilovich, D. I. Activation of dendritic cells via inhibition of Jak2/STAT3 signaling J. Immunol. 2005, 175 (7) 4338-46
18. Imada, K.; Leonard, W. J. The Jak-STAT pathway Mol. Immunol. 2000, 37 (1-2) 1-11
19. Kortylewski, M.; Yu, H. Role of Stat3 in suppressing anti-tumor immunity Curr. Opin. Immunol. 2008, 20 (2) 228-33
20. Vicari, A. P.; Caux, C.; Trinchieri, G. Tumour escape from immune surveillance through dendritic cell inactivation Semin. Cancer Biol. 2002, 12 (1) 33-42
21. Zou, W. Immunosuppressive networks in the tumour environment and their therapeutic relevance Nat. Rev. Cancer 2005, 5 (4) 263-74
22. Yue, P.; Turkson, J. Targeting STAT3 in cancer: how successful are we Expert Opin. Invest. Drugs 2009, 18 (1) 45-56
23. Cejka, D.; Losert, D.; Wacheck, V. Short interfering RNA (siRNA): tool or therapeutic Clin. Sci. (London) 2006, 110 (1) 47-58
24. Kawasaki, H.; Taira, K.; Morris, K. V. siRNA induced transcriptional gene silencing in mammalian cells Cell Cycle 2005, 4 (3) 442-8
25. Hede, K. Blocking cancer with RNA interference moves toward the clinic J. Natl. Cancer Inst. 2005, 97 (9) 626-8
26. Thomas, M.; Lu, J. J.; Chen, J.; Klibanov, A. M. Non-viral siRNA delivery to the lung Adv. Drug Delivery Rev. 2007, 59 (2-3) 124-33
27. Alshamsan, A.; Haddadi, A.; Incani, V.; Samuel, J.; Lavasanifar, A.; Uludag, H. Formulation and delivery of siRNA by oleic acid and stearic acid modified polyethylenimine Mol. Pharmaceutics 2009, 6 (1) 121-33
28. Alshamsan, A.; Hamdy, S.; Samuel, J.; El-Kadi, A. O.; Lavasanifar, A.; Uludag, H. The induction of tumor apoptosis in B16 melanoma following STAT3 siRNA delivery with a lipid-substituted polyethylenimine Biomaterials 2010, 31 (6) 1420-8
29. Zhang, X. Q.; Intra, J.; Salem, A. K. Comparative study of poly (lactic-co-glycolic acid)-poly ethyleneimine-plasmid DNA microparticles prepared using double emulsion methods J. Microencapsulation 2008, 25 (1) 1-12
30. Lutz, M. B.; Kukutsch, N.; Ogilvie, A. L.; Rossner, S.; Koch, F.; Romani, N.; Schuler, G. An advanced culture method for generating large quantities of highly pure dendritic cells from mouse bone marrow J. Immunol. Methods 1999, 223 (1) 77-92
31. Incani, V.; Tunis, E.; Clements, B. A.; Olson, C.; Kucharski, C.; Lavasanifar, A.; Uludag, H. Palmitic acid substitution on cationic polymers for effective delivery of plasmid DNA to bone marrow stromal cells J. Biomed. Mater. Res., Part A 2007, 81 (2) 493-504 (Pubitemid 46668865)
32. Alshamsan, A.; Hamdy, S.; Das, S.; Lavasanifar, A.; Samuel, J.; El-Kadi, A. O. Bone Marrow Derived Dendritic Cells are More Suitable than Dendritic Cell Line DC2.4 to Study Tumor-Mediated Suppression of DC Maturation through STAT3 Hyperactivation J. Pharm. Pharm. Sci. 2010, 13 (1) 21-26
33. Elamanchili, P.; Diwan, M.; Cao, M.; Samuel, J. Characterization of poly(D, L-lactic-co-glycolic acid) based nanoparticulate system for enhanced delivery of antigens to dendritic cells Vaccine 2004, 22 (19) 2406-12
34. Buettner, R.; Mora, L. B.; Jove, R. Activated STAT Signaling in Human Tumors Provides Novel Molecular Targets for Therapeutic Intervention Clin. Cancer Res. 2002, 8, 945-954
35. Hirano, T.; Ishihara, K.; Hibi, M. Roles of STAT3 in mediating the cell growth, differentiation and survival signals relayed through the IL-6 family of cytokine receptors Oncogene 2000, 19 (21) 2548-56
36. Yu, H.; Pardoll, D.; Jove, R. STATs in cancer inflammation and immunity: a leading role for STAT3 Nat. Rev. Cancer 2009, 9 (11) 798-809
37. Mueller, D. L. Mechanisms maintaining peripheral tolerance Nat. Immunol. 2010, 11 (1) 21-7
38. Knutson, K. L.; Disis, M. L. Tumor antigen-specific T helper cells in cancer immunity and immunotherapy Cancer Immunol. Immunother. 2005, 54 (8) 721-8
39. Chaput, N.; Conforti, R.; Viaud, S.; Spatz, A.; Zitvogel, L. The Janus face of dendritic cells in cancer Oncogene 2008, 27 (45) 5920-31
40. Graness, A.; Poli, V.; Goppelt-Struebe, M. STAT3-independent inhibition of lysophosphatidic acid-mediated upregulation of connective tissue growth factor (CTGF) by cucurbitacin I Biochem. Pharmacol. 2006, 72 (1) 32-41
41. Seo, I. A.; Lee, H. K.; Shin, Y. K.; Lee, S. H.; Seo, S. Y.; Park, J. W.; Park, H. T. Janus Kinase 2 Inhibitor AG490 Inhibits the STAT3 Signaling Pathway by Suppressing Protein Translation of gp130 Korean J. Physiol. Pharmacol. 2009, 13 (2) 131-8
42. Kishimoto, T.; Akira, S.; Narazaki, M.; Taga, T. Interleukin-6 family of cytokines and gp130 Blood 1995, 86 (4) 1243-54
43. Molavi, O.; Mahmud, A.; Hamdy, S.; Hung, R.; Samuel, J.; Lai, R.; Lavasanifar, A. Development of a poly(D, L-lactic-co-glycolic acid) (PLGA) nanoparticle formulation of STAT3 inhibitor JSI-124: Implication for cancer immunotherapy Mol. Pharmaceutics 2010, 7 (2) 364-74
44. De Rosa, G.; Quaglia, F.; La Rotonda, M. I.; Appel, M.; Alphandary, H.; Fattal, E. Poly(lactide-co-glycolide) microspheres for the controlled release of oligonucleotide/polyethylenimine complexes J. Pharm. Sci. 2002, 91 (3) 790-9
45. Patil, Y. B.; Swaminathan, S. K.; Sadhukha, T.; Ma, L.; Panyam, J. The use of nanoparticle-mediated targeted gene silencing and drug delivery to overcome tumor drug resistance Biomaterials 2010, 31 (2) 358-65
46. Bala, I.; Hariharan, S.; Kumar, M. N. PLGA nanoparticles in drug delivery: the state of the art Crit. Rev. Ther. Drug Carrier Syst. 2004, 21 (5) 387-422
47. Waeckerle-Men, Y.; Groettrup, M. PLGA microspheres for improved antigen delivery to dendritic cells as cellular vaccines Adv. Drug Delivery Rev. 2005, 57 (3) 475-82
48. Walter, E.; Dreher, D.; Kok, M.; Thiele, L.; Kiama, S. G.; Gehr, P.; Merkle, H. P. Hydrophilic poly(DL-lactide-co-glycolide) microspheres for the delivery of DNA to human-derived macrophages and dendritic cells J. Controlled Release 2001, 76 (1-2) 149-68
49. Panyam, J.; Zhou, W. Z.; Prabha, S.; Sahoo, S. K.; Labhasetwar, V. Rapid endo-lysosomal escape of poly(DL-lactide-co-glycolide) nanoparticles: implications for drug and gene delivery FASEB J. 2002, 16 (10) 1217-26
50. Shen, H.; Ackerman, A. L.; Cody, V.; Giodini, A.; Hinson, E. R.; Cresswell, P.; Edelson, R. L.; Saltzman, W. M.; Hanlon, D. J. Enhanced and prolonged cross-presentation following endosomal escape of exogenous antigens encapsulated in biodegradable nanoparticles Immunology 2006, 117 (1) 78-88
51. Makino, K.; Ohshima, H.; Kondo, T. Transfer of protons from bulk solution to the surface of poly(L-lactide) microcapsules J. Microencapsulation 1986, 3 (3) 195-202
52. Johnson-Leger, C.; Christensen, J.; Klaus, G. G. CD28 co-stimulation stabilizes the expression of the CD40 ligand on T cells Int. Immunol. 1998, 10 (8) 1083-91
53. Yang, Y.; Wilson, J. M. CD40 ligand-dependent T cell activation: requirement of B7-CD28 signaling through CD40 Science 1996, 273 (5283) 1862-4
54. Brunner, C.; Seiderer, J.; Schlamp, A.; Bidlingmaier, M.; Eigler, A.; Haimerl, W.; Lehr, H. A.; Krieg, A. M.; Hartmann, G.; Endres, S. Enhanced dendritic cell maturation by TNF-alpha or cytidine-phosphate-guanosine DNA drives T cell activation in vitro and therapeutic anti-tumor immune responses in vivo J. Immunol. 2000, 165 (11) 6278-86
55. Mariotti, S.; Sargentini, V.; Marcantonio, C.; Todero, E.; Teloni, R.; Gagliardi, M. C.; Ciccaglione, A. R.; Nisini, R. T-cell-mediated and antigen-dependent differentiation of human monocyte into different dendritic cell subsets: a feedback control of Th1/Th2 responses FASEB J. 2008, 22 (9) 3370-9
56. Yoshida, M.; Babensee, J. E. Molecular aspects of microparticle phagocytosis by dendritic cells J. Biomater. Sci., Polym Ed 2006, 17 (8) 893-907
57. Waeckerle-Men, Y.; Scandella, E.; Uetz-Von Allmen, E.; Ludewig, B.; Gillessen, S.; Merkle, H. P.; Gander, B.; Groettrup, M. Phenotype and functional analysis of human monocyte-derived dendritic cells loaded with biodegradable poly(lactide-co-glycolide) microspheres for immunotherapy J. Immunol. Methods 2004, 287 (1-2) 109-24